Aclaris Therapeutics (ACRS) Tops Q1 EPS by 2c
Tweet
Share
E-mailGet Alerts ACRS Hot Sheet
Join SI Premium – FREE
Aclaris Therapeutics (NASDAQ: ACRS) reported Q1 EPS of ($0.12), $0.02 better than the analyst estimate of ($0.14). Revenue for the quarter came in at $1.46 million versus the consensus estimate of $4.09 million.
For earnings history and earnings-related data on Aclaris Therapeutics (ACRS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- American Outdoor Brands (AOUT) Tops Q4 EPS by 14c
- StablecoinX begins Nasdaq trading after SPAC merger closes
- Moderna outlines three-horizon growth strategy at 2026 Science Day
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
